29 April, 2016
Roche has announced that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for treating adult patients with advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) activating mutations. The most common type of lung cancer is NSCLC, which is the major cause of cancer-related death in Europe and across the world. Nearly 10-15 percent of Europeans with NSCLC have tumors with EGFR-activating mutations, which represents an estimated 33,000 cases in Europe per year, or 90 every day.
“Patients with EGFR mutated lung cancer who were treated with the combination of Avastin plus Tarceva lived significantly longer without their disease progressing compared to patients treated with Tarceva alone. We are delighted that this strategy of combining targeted medicines has improved patient outcomes. Today’s CHMP opinion brings us one step closer to providing this combination therapy option to patients,” said Sandra Horning, M.D., Chief Medical Officer and Global Head of Product Development.
Avastin and Tarceva each target pathways which are known as key drivers in the development and growth of tumors. Results of other clinical studies also support the beneficial effect of Avastin plus which proves that the combination is effective and tolerable.